Wall Street Zen Upgrades Sarepta Therapeutics Stock Rating

Analysts raise stock from "sell" to "hold" rating for the biotech company.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen, a research firm, has upgraded its rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) from a "sell" to a "hold" rating in a new research report. The upgrade comes as several other analysts have also recently weighed in on the stock, with some maintaining a "buy" rating and others lowering their price targets.

Why it matters

Sarepta Therapeutics is a key player in the rare disease drug development space, particularly for Duchenne muscular dystrophy (DMD) treatments. The company's stock performance and analyst ratings can impact investor sentiment and the overall outlook for the business.

The details

In the research note, Wall Street Zen cited a number of factors in its decision to upgrade the Sarepta Therapeutics stock rating, including the company's recent financial results and pipeline progress. The firm also noted the mixed views from other analysts covering the stock, with some maintaining bullish stances while others have grown more cautious.

  • Sarepta Therapeutics stock opened at $16.76 on Friday, February 28, 2026.

The players

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

Sarepta Therapeutics

A biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, including Duchenne muscular dystrophy.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The mixed analyst views on Sarepta Therapeutics reflect the complex and competitive landscape for rare disease drug developers. While the company has made progress, there are still uncertainties around its pipeline and financial performance that will require close monitoring by investors.